瑞替普酶治疗下肢深静脉血栓形成的临床观察  

Reteplase thrombolytic therapy on the lower extremity deep venous thrombosis

作　　者：张昌列[1] 宋志红[1] 

机构地区：[1]山东大学附属临沂市人民医院血管介入科,276000

出　　处：《重庆医学》2015年第2期207-208,211,共3页Chongqing medicine

摘　　要：目的探讨下肢深静脉血栓(DVT)的有效治疗方法。方法对该院60例下肢DVT患者进行回顾性分析,32例予瑞替普酶溶栓治疗(瑞替普酶溶栓组),与随机选取同期予重组链激酶溶栓治疗28例(重组链激酶溶栓组)作对比。治疗期间观察患肢变化和有无不良反应,对疗效进行评价。结果两组患者临床全部达到有效,愈显率相比瑞替普酶溶栓组高于重组链激溶栓组,差异有统计学意义(P<0.05)。不良反应比较,瑞替普酶溶栓组低于重组链激溶栓组,但两组差异无统计学意义(P>0.05)。随访期间两组均未见复发病例。结论瑞替普酶治疗下肢深静脉血栓形成是有效的、安全的。Objective To investigate the treatment of the lower extremity deep venous thrombosis .Methods Sixty patients with lower extremity deep venous thrombosis were analyzed retrospectively .Thirty two patients underwent reteplase thrombosis ,and 28 patients underwent recombinant streptokinase thrombosis ;the effects of each group were compared;and the various complications and adverse events were observed .Results Patients in two groups were all effectively treated ,and the effective rate of reteplase group was higher than recombinant streptokinase group （P0 .05） .During the follow‐up ,there was no reoccurrence in all 60 patients .Conclusion Reteplase thrombolytic therapy for the lower extremity deep venous thrombosis is safe and effective .

关 键 词：静脉血栓形成 下肢 栓塞  治疗性 瑞替普酶 重组链激酶 

分 类 号：R542.22[医药卫生—心血管疾病]